Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

The Map of the Disease: Anatomical Subtypes

At a Glance

Cholangiocarcinoma (bile duct cancer) is divided into three subtypes based on its location: intrahepatic (inside the liver), perihilar (exiting the liver), and distal (near the pancreas). Your tumor's exact location dictates your specific surgical options and targeted therapies.

While all cholangiocarcinoma (CCA) begins in the bile ducts, the location of the tumor determines almost everything about your treatment journey. Doctors divide CCA into three distinct anatomical subtypes. These are not just different “spots” for the same cancer; they have different biological drivers, surgical requirements, and long-term outlooks [1][2].

Tip: Ask your doctor to draw a diagram of your biliary tract and mark exactly where your tumor is located. Having a visual aid can make understanding your surgical options much easier.

The Three Anatomical Subtypes

1. Intrahepatic Cholangiocarcinoma (iCCA)

This subtype begins in the small bile ducts inside the liver parenchyma [1].

  • Molecular Profile: iCCA is unique because it often contains “targetable” genetic mutations. Specifically, “small-duct” iCCA is frequently driven by FGFR2 fusions or IDH1 mutations [3].
  • Treatment Logic: If the cancer is caught early enough and is confined to the liver, the primary goal is usually a hepatectomy (surgical removal of a portion of the liver) [4]. However, because these tumors often do not cause early symptoms (like jaundice), many patients are diagnosed at a more advanced stage and will start their journey with systemic therapy instead [5].

2. Perihilar Cholangiocarcinoma (pCCA)

Also known as a Klatskin tumor, this begins at the hilum, the point where the right and left hepatic ducts join and exit the liver [6].

  • Biological Behavior: These are often the most surgically challenging. Because they sit at a major “intersection” of blood vessels and ducts, they frequently involve the portal vein or hepatic artery [6][7].
  • Treatment Logic: Surgery often requires removing the extrahepatic bile ducts along with a major section of the liver [8]. In very specific, early-stage cases, liver transplantation may be an option, offering better survival than traditional surgery for some patients [9][10].

3. Distal Cholangiocarcinoma (dCCA)

This starts in the bile duct outside the liver, closer to where the duct enters the small intestine and passes through the pancreas [11].

  • Clinical Presentation: Because the duct is narrow here, even a tiny tumor can cause an immediate “backup” of bile, leading to early symptoms like jaundice [12].
  • Treatment Logic: Because of its proximity to the pancreas, the standard surgery is often a Whipple procedure (pancreaticoduodenectomy), the same surgery used for pancreatic cancer [13].

Why Anatomy Dictates Your Strategy

The location of your tumor serves as the “blueprint” for your medical team. The table below illustrates how these subtypes differ in their clinical approach.

Feature Intrahepatic (iCCA) Perihilar (pCCA) Distal (dCCA)
Common Surgery Liver Resection [4] Hilar Resection + Liver Resection [8] Whipple Procedure [13]
Targeted Therapy High (FGFR2, IDH1) [3] Limited [14] Limited [15]
Transplant Option Generally no Yes (select cases) [9] No
First Symptom Often vague/none [5] Jaundice [16] Jaundice [12]

Molecular Heterogeneity

It is important to understand that iCCA, pCCA, and dCCA are molecularly distinct [1]. This means that a drug that works for a tumor inside the liver might not work for one near the pancreas [15]. This “molecular heterogeneity” is why your oncologist will likely request a biopsy or genomic testing specifically tailored to your subtype to find the most effective treatment for your unique biology [17].

Common questions in this guide

What are the different types of cholangiocarcinoma?
Cholangiocarcinoma is divided into three main subtypes based on its anatomical location. These are intrahepatic (inside the liver), perihilar (where the ducts exit the liver), and distal (outside the liver, near the pancreas).
What is a Klatskin tumor?
A Klatskin tumor is another medical name for perihilar cholangiocarcinoma. It begins at the hilum, which is the intersection where the right and left hepatic bile ducts join together and exit the liver.
How does the location of my bile duct cancer affect my treatment?
The tumor's location completely dictates the surgical approach and available treatments. Tumors inside the liver are often treated with liver resection, perihilar tumors may involve complex hilar resections or transplant, and distal tumors often require a Whipple procedure.
Why is genetic testing important for intrahepatic cholangiocarcinoma?
Intrahepatic cholangiocarcinoma (iCCA) often contains specific, targetable genetic mutations, such as FGFR2 fusions or IDH1 mutations. Genomic testing helps your medical team find targeted drugs that will work best against your specific tumor biology.
Can I get a liver transplant for cholangiocarcinoma?
Liver transplantation can be an option in very specific, early-stage cases of perihilar cholangiocarcinoma. Your oncologist can determine if you are a candidate for specific transplant programs, such as the Mayo Protocol.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific anatomical subtype do I have: intrahepatic, perihilar (Klatskin tumor), or distal?
  2. 2.Because I have the intrahepatic subtype, have we tested for FGFR2 fusions or IDH1 mutations?
  3. 3.For my perihilar diagnosis, am I a candidate for the 'Mayo Protocol' or liver transplantation?
  4. 4.What specific surgical procedure is required for my subtype (e.g., hepatectomy vs. Whipple procedure)?
  5. 5.Could you draw a diagram of my biliary tract and mark exactly where the tumor is located?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?

    Ricci AD, Rizzo A

    Medicina (Kaunas, Lithuania) 2021; (57(12)) doi:10.3390/medicina57121301.

    PMID: 34946246
  2. 2

    Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF).

    Neuzillet C, Decraecker M, Larrue H, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2024; (44(10)):2517-2537 doi:10.1111/liv.15948.

    PMID: 38967424
  3. 3

    Molecular and Pathological Heterogeneity of Synchronous Small and Large Duct Intrahepatic Cholangiocarcinoma-A Case Series.

    Popovska S, Nankov V, Ilcheva B, Dimitrov G

    Current oncology (Toronto, Ont.) 2025; (32(5)) doi:10.3390/curroncol32050255.

    PMID: 40422514
  4. 4

    Management of Intrahepatic Cholangiocarcinoma: A Narrative Review.

    Tsung C, Quinn PL, Ejaz A

    Cancers 2024; (16(4)) doi:10.3390/cancers16040739.

    PMID: 38398130
  5. 5

    Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.

    Schramm C, Sapuk A, Hoyer D, et al.

    Zeitschrift fur Gastroenterologie 2024; (62(1)):37-42 doi:10.1055/a-2207-5519.

    PMID: 38195106
  6. 6

    Diagnostic Approach to Suspected Perihilar Malignancy.

    Solonitsyn E, Dechêne A

    Visceral medicine 2021; (37(1)):3-9 doi:10.1159/000513950.

    PMID: 33718479
  7. 7

    The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature.

    Dilek ON, Güngör F, Acar T, et al.

    The Indian journal of surgery 2021; (83(1)):114-120 doi:10.1007/s12262-020-02259-y.

    PMID: 32410790
  8. 8

    Different biliary tract cancers, same operation: Importance of cancer origin in patients with hilar-invading tumors.

    Ahmad Al-Saffar H, Jansson H, Danielsson O, et al.

    Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 2025; (114(1)):35-43 doi:10.1177/14574969241282480.

    PMID: 39380179
  9. 9

    Liver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: A critical review.

    Andraus W, Tustumi F, Santana AC, et al.

    Hepatobiliary & pancreatic diseases international : HBPD INT 2024; (23(2)):139-145 doi:10.1016/j.hbpd.2024.01.003.

    PMID: 38310060
  10. 10

    Liver Transplant for Cholangiocarcinoma.

    Zamora-Valdes D, Heimbach JK

    Gastroenterology clinics of North America 2018; (47(2)):267-280 doi:10.1016/j.gtc.2018.01.002.

    PMID: 29735023
  11. 11

    Novel Targeted Therapies for Advanced Cholangiocarcinoma.

    Rizzo A, Brandi G

    Medicina (Kaunas, Lithuania) 2021; (57(3)) doi:10.3390/medicina57030212.

    PMID: 33652960
  12. 12

    Real-world impact of the management of advanced perihilar and extrahepatic cholangiocarcinoma on prognosis.

    Decraecker M, Aurillac V, Blanc JF

    Hepatobiliary & pancreatic diseases international : HBPD INT 2026; (25(2)):191-197 doi:10.1016/j.hbpd.2025.12.016.

    PMID: 41535224
  13. 13

    Is radical resection of hilar cholangiocarcinoma plus partial resection of pancreatic head justified for advanced hilar cholangiocarcinoma?

    Liu F, Hu HJ, Ma WJ, et al.

    ANZ journal of surgery 2020; (90(9)):1666-1670 doi:10.1111/ans.15955.

    PMID: 32452116
  14. 14

    Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.

    Akita M, Sofue K, Fujikura K, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2019; (21(2)):226-234 doi:10.1016/j.hpb.2018.07.021.

    PMID: 30170977
  15. 15

    Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

    Kubo S, Shinkawa H, Asaoka Y, et al.

    Liver cancer 2022; (11(4)):290-314 doi:10.1159/000522403.

    PMID: 35978598
  16. 16

    Comparison of clinical characteristics and mortality risk between patients with cholangiocarcinoma: A retrospective cohort study.

    Liu Y, Wang Y, Yu Y, et al.

    Frontiers in surgery 2022; (9()):1037310 doi:10.3389/fsurg.2022.1037310.

    PMID: 36873806
  17. 17

    Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes.

    Pudlarz T, Turpin A, Tissera NS, et al.

    JHEP reports : innovation in hepatology 2025; (7(11)):101550 doi:10.1016/j.jhepr.2025.101550.

    PMID: 41078701

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or oncologist to understand your specific cholangiocarcinoma subtype and the most appropriate treatment options.

Get notified when new evidence is published on Cholangiocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.